For Industry

We have upgraded our innovative approach to designing new types of protein nanostructures based on a defined sequence of interconnected segments.

We present a novel approach for delivering vaccines and other therapeutic nucleic acids, which uses mucoadhesive films consisting of two layers.

The designed CISPAs are preferably based on human-derived ligand-binding proteins, which are divided into two fragments that reassemble in the presence of a selected ligand.

Our technology builds on CRISPR/Cas with tethering – the attachment of a molecule to the Cas9 protein. In our case, the molecule tethered to Cas9 was exonuclease III (EXOIII)

Our SAg of choice was a highly potent and well characterized staphylococcal enterotoxin A (SEA) from S. aureus. Proof-of-concept fusion proteins were designed, where individually inactive split SAg fragments were genetically fused to a single chain variable fragment against B cell antigen CD20 (scFv–CD20).

HCQ is a widely used drug with a few side effects. When administered with nucleic acids, it binds to them and reduces their recognition by cellular receptors.

A class of substituted 4,5'-bithiazoles, unlike conventional topoisomerase II poisons, inhibits human topoisomerase IIα through an alternative ATP-competitive mechanism.

The researchers have developed new antibacterial agents from the class of novel bacterial topoisomerase inhibitors (NBTIs) with innovative right hand side fragments that provide excellent overall antibacterial potency against a wide panel of Gram-positive and Gram-negative bacterial pathogens.

The pivotal feature of deregulated energetic metabolism of cancer cells is posttranslational modification of 6-phosphofructo-1-kinase (PFK1), the key regulatory enzyme of glycolysis.

Nanopore technology is important in biotechnology for applications such as nanopore sensing and nanopore sequencing.

A therapeutic device with therapeutic cells that secrete a combination of therapeutic proteins. The therapeutic cells are stored in a semi-permeable chamber that enables the exchange of nutritional substances and therapeutic proteins.

The Covid-19 pandemic is a major threat to the public health and economies. Effective vaccines based on new technologies represent the main hope to stop it.

We have developed a sample buffer (consisting of a modified RNA stabilisation buffer, the RNA inhibitor Rnasecure, and a polymeric chelator, Chelex100) for the stabilisation of viral RNA and a sampling method that is fast and simple.

The lack of efficient methods to control the major diseases of crops most important to agriculture leads to huge economic losses and seriously threatens global food security.